As a sweltering heat wave hit Europe, a swath of pharma companies and healthcare marketing agencies from around the world ...
Headlining Evaluate’s forecast is Eli Lilly’s diabetes and obesity med tirzepatide, which the Evaluate team figures will be worth more than $70 billion by 2032 (wildpixel/iStock/Getty Images Plus) ...
A newly unsealed whistleblower lawsuit accuses Novartis and Genentech of being at the center of a decades-long kickback ...
The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products ...
Amid efforts in Germany to retool the country’s drug spending, the U.S. is launching an investigation into what the Office of ...
Pharma companies have been part of the global economy and our health systems for centuries. | Pharma companies have been part ...
The ruling marks the end of a case that put Alnylam and Pfizer at loggerheads. In its response to the PMCPA, Alnylam accused ...
With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line ...
After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the cyber ...
Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for ...
AbbVie and Johnson & Johnson are the current big spenders when it comes to TV drug ads in the U.S., but Eli Lilly and Novo ...
A deviation gets flagged on a 2,000-liter batch. The product sits on hold until someone can explain what happened and whether ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results